Regeneron, Bayer’s VEGF Drug Closing The Gap On Lucentis
This article was originally published in The Pink Sheet Daily
Executive Summary
Receptor fusion protein’s Phase II data suggest two potential advantages.
You may also be interested in...
Acucela, Otsuka Enter Deals For Eye Drugs
Early stage and late stage pacts add proof of Japan’s growing interest in the U.S.
Acucela, Otsuka Enter Deals For Eye Drugs
Early stage and late stage pacts add proof of Japan’s growing interest in the U.S.
Bayer/Regeneron Phase III Will Study Eight-Week Dosing With VEGF Trap-Eye
Non-inferiority trial will compare the VEGF Trap-Eye candidate to Genentech’s Lucentis.